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Introduction
Prostatic needle biopsy is being increasingly undertaken in men with raised serum prostate-speci®c antigen (PSA) andaor abnormal digital rectal examination (DRE) to diagnose malignant disease. This practice will inevitably contribute to the more frequent diagnosis of prostatic intra-epithelial neoplasia (PIN). High grade PIN is believed to be a morphological precursor of invasive cancer, particularly for moderately or poorly differentiated disease in the peripheral zone and its potential importance in the detection of early stage prostate cancer is now beginning to be recognised.
Several studies have suggested that when high grade PIN is diagnosed on needle biopsy, there is a signi®cantly increased risk of either undiagnosed concomitant carcinoma or future development of carcinoma that results in a diagnosis of invasive malignancy in around half of these cases (Table 1) . Thus, serial biopsy is frequently recommended to detect early stage cancer. 1 Implementation of these recommendations, would produce a substantial increase in the clinico-pathological workload and costs involved in any strategy to detect early prostate cancer. To emphasise the magnitude of the problem, we present the prevalence of high grade PIN in relation to serum PSA levels and cancer detection rates in needle biopsy series from three different clinical contexts. Future studies may de®ne, by serum PSA, the group of patients with high grade PIN who are at most risk of concomitant cancer and require re-biopsy.
Methods
Prostatic needle core biopsies from three independent clinical settings are examined. All specimens had been routinely processed to paraf®n, sectioned, stained with haematoxylin and eosin in the same laboratory and examined by one histopathologist (MCP). A minimum of six levels were examined from each biopsy. High grade PIN was diagnosed according to the criteria of Drago et al. 2 When high grade PIN was identi®ed in the same prostate as carcinoma, the latter was recorded.
Hospital practice
The results of prostatic needle biopsies examined in diagnostic hospital practice at University College London Hospitals Trust from the NHS or private sector between 1988 and 1994 were reviewed. 1205 men underwent biopsy with an 18 gauge needle during this period. Clinical ®ndings and biopsy protocol were not invariably made available to the pathologist. Indications for biopsy included abnormal DRE, elevated serum PSA ( b 4.0 ngaml), abnormal transrectal ultrasound scan of the prostate (TRUS) or a combination of these. Serum PSA levels were subsequently traced in 454 of these men.
Screening
All men aged between 55 and 70 y registered at one of 12 General Practices in Gwent were invited by mailed personal invitation to attend their surgery for a prostate health check between 1991 and 1993, with local ethical committee approval. Serum was obtained for PSA determination (Hybritech) and DRE then undertaken by the general practitioner and urologist. Men with abnormal DRE or PSA greater than 4.0 ngaml underwent TRUS using a Bruel and Kjaer 1846 machine with a 7 MHz multiplanar probe. Gland volume was estimated using the prolate ellipse formula (0.52 Â height Â length Â width) to predict the serum PSA level corresponding to a PSA density of 0.12 ngamlacc (predicted PSA gland volume Â 0.12) 191 individuals had a suspicious focal hypoechoic lesion greater than 0.5 cm from which two TRUS guided biopsies were taken with an 18 gauge needle and another 21 with a PSA more than 2.0 ngaml greater than the predicted PSA density underwent sextant biopsy. Thus 212 men had biopsies and the mean number of biopsies taken was 2.4 per patient.
Case-®nding
118 consecutive men, aged 50±86 (median and mean 67 y, referred to St. Bartholomew's Hospital, London, between 1993 and 1994 for prostatism or concern about prostate cancer all underwent systematic biopsies irrespective of symptom score, DRE ®ndings, serum PSA and TRUS scan. Each of these investigations was carried out for every patient with written, informed consent; local ethical committee approval had been obtained before commencing this study. Individuals with evidence of locally advanced prostate cancer at their initial out-patient attendance were excluded. Serum for PSA determination (Abbott IMx) was obtained before undertaking DRE or TRUS. TRUS was undertaken with a Siemens Sonoline 150 with a 7.5 MHz probe. Sextant biopsies were obtained with an 18 gauge needle from the posterior and mid-gland on each side, the apex and base adjacent to the midline and any suspicious ultrasonographic abnormalities. The mean number of biopsies taken per patient was 5.6.
Results
Biopsy ®ndings and their relation to serum PSA levels are described in Tables 2±7.
There were notable differences in the prevalence of high grade PIN between the three populations, with detection rates of 11% in hospital practice, 20% in the screened group and 25% at case-®nding. Men undergoing biopsy in hospital practice generally had higher PSA levels than those in the screening or case-®nding groups (Table 4) . Not surprisingly, cancer was therefore more prevalent in the hospital practice than in the screened population or in the case-®nding study. However, high grade PIN was more common in both the case-®nding and screened populations than in hospital practice, even after excluding men with cancer ( Table 2) .
Irrespective of presentation, cancer was statistically signi®cantly more common in men with higher PSA levels (P`0.05, w 2 ). The impact of PSA on the prevalence of high grade PIN was less striking, but there was a trend in all three practices for high grade PIN to be more common in men with lower PSA levels, which reached signi®cance in hospital practice (Tables 5±7). The cost of re-biopsy within the NHS practice at UCL Hospitals Trust, based on an average 300 patients undergoing prostatic biopsies annually in the last three years, with a high grade PIN rate of 11%, at a cost of £132 for TRUS guided sextant biopsies and £50 for histopathological examination, would be an additional £6000 per annum. These costs should be incorporated in protocols for case ®nding or screening for prostate cancer if high grade PIN is to be followed-up routinely.
Discussion
PIN is a pathological abnormality found predominantly in the peripheral zone of the prostate characterised by cytological abnormalities within the duct-acinar structure that are con®ned within an intact or intermittent basal cell layer. 3±5 It may be present as the only abnormality or in association with prostate cancer and can be diagnosed in needle core biopsies, but it is uncommon in transurethral resection specimens. Originally three grades of PIN were described, 6 but since 1989 the classi®cation of PIN has been simpli®ed into`low' grade (grade I) or`high' grade (grades II and III). 2 Strong evidence suggests that high grade PIN may represent a precursor lesion to moderately and poorly differentiated cancer. 7 However, the relationship of low grade PIN to high grade PIN and carcinoma is uncertain ( Table 1 ). The pre-malignant potential of high grade PIN is supported by the following observations: it is found more often in cancerous prostates than benign glands. 6, 8, 9 Similar biomarker abnormalities are observed to be associated with both high grade PIN and cancer. 5 It is commonly present adjacent to smaller malignant lesions, but also often found elsewhere within the prostate harbouring invasive carcinoma consistent with the multifocal nature of malignancy. 9±11 The spatial relationship between high grade PIN and cancer has been consistently demonstrated by whole mount step-sectioning 12 and its clinical importance is emphasised by the diagnosis of prostatic carcinoma in 27±100% of patients selected for re-biopsy following a diagnosis of isolated high grade PIN ( Table 1) .
The prevalence of high grade PIN in three settings, namely routine hospital practice, screening and case®nding was 11, 20 and 25% respectively. The clinical presentation of patients undertaking biopsies differed notably between the centres and the prevalence of high grade PIN increased as lower thresholds for biopsy were adopted. It is unlikely that epidemiological factors account for this variation and no difference in the prevalence of prostate cancer between Wales and London has been documented and both groups from London were recruited from similar populations. Nor would differences in histopathological interpretation entirely explain the different incidence of PIN as the same histopathologist examined all the biopsies over a similar time period. Moreover, the 11% prevalence of high grade PIN in the hospital practice is similar to the 16 and 9.5% respectively reported from the Mayo Clinic and Glendale Memorial Hospital in the US. 13 Nevertheless, comparisons should be made with caution in view of dissimilar clinical context and biopsy protocol in each of the three groups.
Several authors have reported that an elevated PSA associated with high grade PIN indicates a signi®cantly increased risk of a subsequent diagnosis of cancer. 14±17 In fact, within all the re-biopsy series summarised in Table 1 , the mean or median PSA is greater than 4 ngaml and in four studies it is greater than 8 ngaml. 1, 15, 17, 18 PIN alone probably does not cause raised serum PSA: it is associated primarily with luminal abnormalities with a relatively intact basal cell layer and intact basement membrane. PSA would therefore not be expected to leak excessively into the vascular compartment. Any apparent relation between PIN and elevated serum PSA suggested in some early studies 19±21 may be accounted for by the possibility of concomitant undiagnosed cancer. 15, 22 Thus, in a study of 65 radical prostatectomy specimens, high grade PIN was found not to contribute to elevated serum PSA 23 and other recent studies also suggest that PIN alone does not increase the serum PSA. 1, 24 We observed similar serum PSA levels in men with benign histological ®ndings and those with high grade PIN, and higher levels in men with cancer.
In each study group, the cancer detection rate was greater in higher PSA ranges, as expected. However, the diagnosis of high grade PIN showed the opposite trend and was more common in patients with lower PSA levels. An inverse relationship between the detection rate for high grade PIN and PSA would also be consistent with its greater prevalence in the case-®nding and screening studies. The tendency for invasive tumours to gradually overgrow areas of PIN 25, 26 would account for the detection of isolated high grade PIN in men with lower PSA levels and high grade PIN associated with invasive cancer on early biopsy in patients with higher serum PSA concentrations.
It is suggested that the prevalence of high grade PIN should be described in relation to serum PSA levels, as is cancer. This may be of particular importance when rates of reporting high grade PIN are being compared between centres and studies. The 11±25% rate in this study may indicate potential problems in management with workload and cost implications. A prospective rebiopsy study is urgently required to investigate the interval to detection of cancer in relation to initial serum PSA concentration in patients with isolated high grade PIN. Our aim must be to distinguish high grade PIN associated with concomitant carcinoma (`missed cancer') in patients possibly requiring radical treatment from isolated PIN that may subsequently progress to invasive disease.
